Correction to: FDA and EMA Biosimilar Approvals

Emily H. Jung, A.B.¹, Ameet Sarpatwari, Ph.D. J.D.¹,
Aaron S. Kesselheim, M.D., J.D., M.P.H.^{1,1}, and Michael S. Sinha, M.D., J.D., M.P.H.^{1,2}

¹Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; ²Harvard-MIT Center for Regulatory Science, Harvard Medical School, Boston, MA, USA.

J Gen Intern Med
DOI: 10.1007/s11606-019-05558-7
© Society of General Internal Medicine 2019

Correction to: J Gen Intern Med

<https://doi.org/10.1007/s11606-019-05408-6>

This paper published with several formatting errors. They have been corrected and the paper has re-published.

Corresponding Author: Ameet Sarpatwari, Ph.D. J.D; Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA (e-mail: asarpawari@bwh.harvard.edu).

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The online version of the original article can be found at <https://doi.org/10.1007/s11606-019-05408-6>